Caroline Seymour | Authors

June 07, 2022

Phase 3 CAIRO5 showed improvements in progression-free survival and overall response with FOLFOXIRI plus bevacizumab in colorectal cancer liver metastases, but the combination demonstrated a toxic safety profile.

June 05, 2022

At the 2022 ASCO Annual Meeting findings from the phase, 3 DETERMINATION trial showed off the survival benefit when adding autologous stem cell transplant and lenalidomide maintenance after RVd treatment for patients with newly diagnosed multiple myeloma.

June 05, 2022

Encouraging efficacy signals in heavily pretreated patients with advanced solid tumor has been demonstrated in AURELIO-03 trial, and will be further evaluated in AURELIO-304.

June 04, 2022

Therapy with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine lead to a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, in patients with previously untreated stage III/IV classical Hodgkin lymphoma.

April 24, 2022

In the prospective, double-blind, phase 2 randomized controlled trial, in which investigators evaluated the efficacy and safety of topical ruxolitinib, a novel gene signature was identified.

February 18, 2022

Mixed results were reported from the phase 2 ARIES clinical trial at the 2022 ASCO GU meeting.